<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808208</url>
  </required_header>
  <id_info>
    <org_study_id>15-009053</org_study_id>
    <nct_id>NCT02808208</nct_id>
  </id_info>
  <brief_title>Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure</brief_title>
  <official_title>A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this phase 1 study is to determine the role of autologous adipose derived
      mesenchymal stem cells in the reduction of hemodialysis arteriovenous fistula failure when
      applied during the time of surgical creation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodialysis outflow vein diameter</measure>
    <time_frame>Baseline to 12 months after AVF creation</time_frame>
    <description>Diameter of outflow vein by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis AVF Blood flow</measure>
    <time_frame>Baseline to 12 months after AVF creation</time_frame>
    <description>blood flow by ultrasound or dialysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <condition>Vascular Access Complication</condition>
  <arm_group>
    <arm_group_label>Group 1 AMSC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients have tissue biopsy and Adipose Derived Mesenchymal Stem Cells (AMSC) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adipose Derived Mesenchymal Stem Cells (AMSC)</intervention_name>
    <description>This group will receive Autologous stem cells derived from own fat biopsy.</description>
    <arm_group_label>Group 1 AMSC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient between 18 and 85 years old

          -  Patient currently on hemodialysis or pre-dialysis and planned creation of an upper
             extremity AV fistula with suitable anatomy

          -  Ability to communicate meaningfully with investigative staff, competence to give
             written informed consent, and ability to comply with entire study procedures

          -  Life expectancy of at least 24 months

        Exclusion Criteria

          -  Malignancy or treatment for malignancy within the previous 6 months

          -  Immunodeficiency including AIDS / HIV or Active autoimmune disease

          -  Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous
             intravascular thrombotic events

          -  Pregnancy or breast feeding

          -  Treatment with any investigational drug/ device within 60 days prior to study entry or
             Any other condition which in the judgment of the investigator would preclude adequate
             evaluation of the safety and efficacy of AMSCs and the AVF

          -  Employees of the sponsor or patients who are employees or relatives of the
             investigator

          -  History of failed organ transplant on immunosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Misra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sanjay Misra, M.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

